Skip to main content
. 2017 Dec 26;9(4):5169–5183. doi: 10.18632/oncotarget.23704

Figure 5. Assessment of bioavailability and animal behavior upon SAM-treatment.

Figure 5

(A) The average level of SAM in control and the experimental group receiving 80 mg/kg/day ofSAM as determined by the SAM ELISA. Results are obtained from the analysis of serum from four animals in each group. (***P < 0.001). (B) Novel object recognition test of control and SAM-treated mice. Average Discrimination ratio (time spent with the novel object/ total time spent with both object). No significant differences in cognitive abilities are detected between control and SAM-treated groups. (C-G) Different parameters determined by the open field test of control and SAM-treated mice also showed no significant difference between control and SAM-treated animals. Results are shown as mean ± SEM (n=3 for each group of CD-1 nude mice), and statistical analyses were done using student's t-test. (H) A summary of biological processes shown to be affected by SAM as determined in this study includes cell proliferation, invasion, apoptosis in vitro and tumorigenesis and metastasis in vivo.